Paul Burke (@ontargt) header
Paul Burke (@ontargt) profile picture

Scientific & strategic direction for biopharma, focused on translating research-stage technology breakthroughs into products. New modalities/nanotech/delivery.

Cambridge, MA
Joined December 2011
Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)Photo by Paul Burke (@ontargt)
Paul Burke retweeted
Use of GalNAc-based liver targeting to improve the safety profile of an effective small molecule. The result of a terrific collaboration between the non-profit, academic, and industrial sectors ==>> @gatesfoundation @UWMolES @UWBioE science.org/doi/10.1126/scia…
2
7
697
Use of GalNAc-based liver targeting to improve the safety profile of an effective small molecule. The result of a terrific collaboration between the non-profit, academic, and industrial sectors ==>> @gatesfoundation @UWMolES @UWBioE science.org/doi/10.1126/scia…
2
7
697
RNA-editing drugs advance into clinical trials bit.ly/445OqZV ADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ones. Find out more in this news article published today
1
64
3
227
19,694
Three cheers for intact TLR9 inflammatory signalling!
Love the cross-talk between development and innate defenses. Examples include antiviral RNAi being repurposed for developmental miRNA biology, or conversely, developmental TLRs being repurposed for defense. Now we see TLR9 also contributing to memory rdcu.be/dCHcO"
2
322
Delivery, delivery, delivery! Join us in Siracusa, Italy from April 4-7 to discuss new advances in nucleic acid delivery and how to solve the remaining challenges! Don't miss this opportunity. Abstract deadline is March 15, 2024. Register here: engconf.us/conferences/biote…
1
5
25
1,687
Paul Burke retweeted
We are excited to share our views on extra-hepatic delivery in @NatureNano. Congrats to all our exceptional team members who did most of the heavy lifting and the editorial team and reviewers for their feedback! Happy New Year and Happy Reading! nature.com/articles/s41565-0…
9
25
2
171
16,309
#Breaking: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease. Learn more: bit.ly/4apMw9p
23
129
35
454
75,953
If you use the @wsj App and have not recently updated it, DON’T DO IT!!! It is the New Coke of iPad Apps. And it appears there is no way to roll back to the earlier version.😠
Replying to @WSJ
@WSJ We're happy to share we’ve reintroduced beloved features, and new enhancements, to optimize the WSJ iPad experience. Update your WSJ mobile app to enjoy these offerings now, including the reintroduction of our vertical What’s News layout. More updates will be coming soon!
2
3
544
It’s a big mistake to weigh commercial opportunity (often done by 25 yo consultants) over likelihood of patient impact (usually done with gray hair and wrinkle)…. Just saying!
8
20
1
125
49,074
Promise of superhero status makes injections acceptable! “As influencers share stories of physiological transformations, more people are seeking out experimental treatments: ‘If I can be a superhero and function at my absolute optimum, why wouldn’t I?’” wsj.com/articles/peptide-inj…
1
380